Mon - Fri 10:00-18:00
Johannesburg, Fourways

CDC: U.S. Coronavirus-Related Deaths to Start Falling Next Week

Thanks largely to a decline in one coronavirus hotspot, the number of deaths from COVID-19 — the disease it can trigger — should begin to fall next week. That, at least, was the prediction of Dr. Robert Redfield, director of the government’s Centers for Disease Control and Prevention (CDC).

Following persistent urging from healthcare professionals, combined with mandates from many municipalities and states, much of the population seems to be complying with measures such as social distancing and habitual mask-wearing in public.

Four doctors with masks walking down hospital corridor.

Image source: Getty Images.

This is one reason Redfield is sounding an optimistic note on what’s to come soon. “I think we’re going to start to see a decline in mortality across the country now next week as we continue to get control of these cases,” he said in an interview with Dr. Howard Bauchner of the influential Journal of the American Medical Association.

If his hope is realized, fatalities from the disease will start to follow the trajectory of total cases, which, on a national level, have been on the decline for nearly one month. On Thursday, for example, according to data compiled by The Wall Street Journal, the number of daily new cases was below 50,000 for the sixth day in a row, at a total of slightly over 44,000.

There’s currently no widely approved drug to treat coronavirus/COVID-19, nor is there a vaccine.

Numerous biotech and pharmaceutical companies are developing such products. A few — such as Moderna‘s mRNA-1273 vaccine candidate — are in late-stage clinical trials.

One drug, the repurposed remdesivir from Gilead Sciences is being used to treat the disease. However, it has received only Food and Drug Administration Emergency Use Authorization, only for use in certain instances.

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Gilead Sciences wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 1, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Reply

Select your currency
ZAR South African rand